Skip to the main content

Review article

Liver Transplantation in Recipients with Malignant Disease

Tajana Filipec Kanižaj
Maja Mijić
Miloš Lalovac
Božena Delija
Ivona Šarić
Hrvoje Premec
Sandra Tipurić
Stjepan Skok
Nikola Sobočan


Full text: croatian pdf 96 Kb

page 251-256

downloads: 178

cite

Full text: english pdf 96 Kb

page 251-251

downloads: 214

cite


Abstract

Surgical resection and liver transplantation are the only potentially curative treatment options for primary liver cancers such as hepatocellular carcinoma and cholangiocarcinoma, as well as isolated liver metastatic disease of various primary tumors. Generally, these tumors are highly aggressive. At the time of diagnosis patients often present an advanced stage of disease and only a small proportion may be eligible for radical surgical resection. Liver transplantation has gained increased acceptance as a potentially best curative treatment option in highly selected groups of patients because it offers an extension of the limits of safe surgical resection by applying various transplant surgical techniques and is also the cure of baseline liver disease which serves as a substrate for the formation of new tumors. Due to the high risk of disease recurrence, even with R0 resection, the best treatment results are achieved with (neo)adjuvant oncological treatment before and after liver transplantation, as well as an individual approach to immunosuppressive therapy. Transplant oncology is a relatively new multidisciplinary field that involves not only extended surgical techniques but also incorporates research focused on the best approach to candidate selection, (neo)adjuvant oncological treatment, tumor and transplant immunology, cancer gene profiling and immunogenomics.

Keywords

liver transplantation; malignant diseases; neoadjuvant oncological treatment; transplantation oncology

Hrčak ID:

315866

URI

https://hrcak.srce.hr/315866

Publication date:

9.4.2024.

Article data in other languages: croatian

Visits: 959 *